阿斯利康Brilinta药物获巨额收益

阿斯利康正在庆祝备受关注的具有巨大潜在价值的倍林达药物的试验营收结果，该药通过数据证明，血液稀释剂能够明显降低有心脏病发作史的病人心血管血栓疾病的发生。

巨大的Pegasus-TIMI 54研究是一项涉及超过21000名患者的大规模试验，研究评估了对研究开始前1到3年内有心梗病史的患者给予一天两次倍林达（替格瑞洛）片剂60 mg或90 mg外加低剂量阿司匹林这种疗法，对其动脉粥样硬化的二级预防效果，主要疗效终点是心血管死亡、心肌梗死或者卒中的复合终点。初步分析没有发现任何预期外的安全性问题，目前正在进行数据的全面评估。该药对心肌梗塞或中风的初步疗效非常成功，本次试验的全部结果将提交到2015年科学会议上。

阿斯利康全球心血管和代谢疾病药物研发的领头人ElisabethBjörk发言称：Pegasus研究建立的数据来自PLATO试验中18000名急性冠脉综合征病人并“提供了长期预防心血管事件潜在作用的重要临床见解”。该公司目前已将Pegasus数据送至监管机构力图扩大倍林达药物的使用范围。

倍林达是阿斯利康未来前景的关键所在，它发展的非常缓慢但其作用是值得肯定的。倍林达第三季度销售额达到1.27亿美元，比上年同期增长75%。（转化医学网360zhyx.com）

本文系转化医学网原创编译整理，如需转载，请联系info@360zhyx.com。

附原文：

AZ gets boost from Brilinta data
AstraZeneca is celebrating after top-line results from a closely-watched trial of its potential blockbuster Brilinta demonstrated that the bloodthinner demonstrated statistically significant reductions in major cardiovascular thrombotic events in patients with a history of heart attack.
The huge Pegasus-TIMI 54 study, involving over 21,000 patients, assessed twice-daily Brilinta (ticagrelor) at either 60mg or 90mg, plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. The primary efficacy endpoint, a composite of CV death, myocardial infarction or stroke, was successfully met and the complete results will be submitted to a scientific meeting in 2015.
Elisabeth Bjork, head of cardiovascular and metabolic diseases at AstraZeneca said the Pegasus study builds on data from the 18,000-patient PLATO acute coronary syndrome trial and “offers important clinical insights into its potential role for the longer-term prevention of cardiovascular events”. The company will now present the Pegasus data to regulators in a bid to significantly expand use of Brilinta.
Brilinta is key to AstraZeneca's future prospects and is growing slowly but surely, with third-quarter sales reaching $127 million, a leap of 75% on the like, year-earlier period.